Blueprint Medicines (BPMC) Stock Forecast & Price Target

$88.69 -6.96 (-7.28%)

(As of 11/15/2024 08:54 PM ET)

Blueprint Medicines - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
1

Hold
6

Buy
14

Based on 21 Wall Street analysts who have issued ratings for Blueprint Medicines in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 1 has given a sell rating, 6 have given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for BPMC.

Consensus Price Target

$122.11
37.68% Upside

According to the 21 analysts' twelve-month price targets for Blueprint Medicines, the average price target is $122.11. The highest price target for BPMC is $168.00, while the lowest price target for BPMC is $76.00. The average price target represents a forecasted upside of 37.68% from the current price of $88.69.

BPMC Analyst Ratings Over Time

Type	Current Forecast 11/19/23 to 11/18/24	1 Month Ago 10/20/23 to 10/19/24	3 Months Ago 8/21/23 to 8/20/24	1 Year Ago 11/19/22 to 11/19/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	7 Buy rating(s)
Hold	6 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$122.11	$120.00	$120.00	$75.43
Forecasted Upside	37.68% Upside	39.53% Upside	28.76% Upside	18.49% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

The Harvard Business School proved his stock picking system works (Ad)

If you missed our last email, I hope you see this one. You see, this Tuesday afternoon we’re sitting down with the #1 ranked stock picker in North America. A man who’s beat out 16,000 stock market professionals on Sum Zero to claim the top spot… He was amongst the first to recommend many of today’s most dominant companies, including both Apple and Nvidia. And for the first time on a large scale, he’s going to share the stock rating system that made it all possible… Not only has this system been proven to generate significant alpha by The Harvard Business School… It also earned a patent from the US government… The technology behind this system is out of this world, and our #1 stock picker has agreed to let us test a number of stocks against it.

Follow this link here we’ll add you to the guest list.

BPMC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BPMC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Blueprint Medicines Stock vs. The Competition

Type	Blueprint Medicines	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	37.68% Upside	28,591.96% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent BPMC News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$135.00 ➝ $135.00	+41.14%
11/15/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$135.00 ➝ $135.00	+41.14%
11/14/2024	Wedbush 4 of 5 stars		Reiterated Rating	Outperform	$135.00	+41.14%
11/14/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$126.00	+30.06%
10/31/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$153.00 ➝ $151.00	+70.37%
10/24/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Dai Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$88.00	+4.27%
The Harvard Business School proved his stock picking system works (Ad) If you missed our last email, I hope you see this one. You see, this Tuesday afternoon we’re sitting down with the #1 ranked stock picker in North America. A man who’s beat out 16,000 stock market professionals on Sum Zero to claim the top spot… He was amongst the first to recommend many of today’s most dominant companies, including both Apple and Nvidia. And for the first time on a large scale, he’s going to share the stock rating system that made it all possible… Not only has this system been proven to generate significant alpha by The Harvard Business School… It also earned a patent from the US government… The technology behind this system is out of this world, and our #1 stock picker has agreed to let us test a number of stocks against it. Follow this link here we’ll add you to the guest list.
8/2/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kusy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$130.00 ➝ $138.00	+42.18%
8/2/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$112.00 ➝ $127.00	+30.24%
7/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$75.00 ➝ $105.00	-4.93%
7/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$110.00 ➝ $115.00	-3.04%
7/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$114.00 ➝ $125.00	+11.91%
6/7/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$125.00 ➝ $125.00	+19.90%
5/14/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$140.00	+29.57%
5/6/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
5/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$121.00 ➝ $168.00	+57.78%
5/6/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform	$50.00 ➝ $97.00	-9.51%
5/3/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$65.00 ➝ $76.00	-29.10%
5/3/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$78.00 ➝ $104.00	-5.98%
4/26/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$120.00 ➝ $130.00	+40.00%
12/22/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy ➝ Strong-Buy	$85.00 ➝ $100.00	+16.37%
6/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$48.00 ➝ $43.00	-26.14%
5/5/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:37 AM ET.

BPMC Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Blueprint Medicines is $122.11, with a high forecast of $168.00 and a low forecast of $76.00.
: 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There is currently 1 sell rating, 6 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BPMC shares.
: According to analysts, Blueprint Medicines's stock has a predicted upside of 37.68% based on their 12-month stock forecasts.
: Blueprint Medicines has been rated by research analysts at HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, UBS Group, Wedbush, and Wells Fargo & Company in the past 90 days.
: Analysts like Blueprint Medicines less than other "medical" companies. The consensus rating score for Blueprint Medicines is 2.71 while the average consensus rating score for "medical" companies is 2.80. Learn more on how BPMC compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

The Harvard Business School proved his stock picking system works (Ad)

Follow this link here we’ll add you to the guest list.

This page (NASDAQ:BPMC) was last updated on 11/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blueprint Medicines (BPMC) Stock Forecast & Price Target